Glutaryl cephalosporin amidase from pseudomonas diminuta bs-203
CA 2423161 A1 · Owner: Bristol-Myers Squibb Company · Inventors: Tonzi, Sean M.; Liu, Suo Win; Burnett, William V. Jr.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a glutaryl 7-ACA amidase from Pseudomonas diminuta strain BS-203, which catalyzes the hydrolysis of 7-.alpha.-(4carboxylbutanamido)-cephalosporanic acid to 7-aminocephalosporanic acid and glutaric acid. The invention also provides nucleic acid sequences vectors, and host cells useful in the production of this amidase. The glutaryl 7-ACA amidase can be used for the preparation of 7-aminocephalosporanic acid.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 19, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 19, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 19, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.